Skip to main content
. 2022 Feb 19;41:68. doi: 10.1186/s13046-022-02272-x

Fig. 5.

Fig. 5

A Schematic illustration of PNP@R@M-T developed for efficient and selective reprogramming of M2-like macrophages and enhanced cancer immunotherapy via M2pep-mediated endocytosis. B-F Inhibitory effects of PNP@R@M-T on tumor growth in vivo. B Schematic illustration of induction and treatment of B16-OVA tumors in C57BL/6 mice. C Body weights of mice treated with PBS, R848, PNP@R, PNP@R@M-S, and PNP@R@M-T. D The survival rate was analyzed by the log-rank test (n = 10 mice). E B16-OVA tumor growth. n = 6 mice. F Macroscopic images of tumors taken 18 days after the initiation of treatment. Representative images from 6 mice per group are shown [28]